---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031133"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:29:55.231569+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRx CEO resigns; Chairman Javitt takes interim CEO; shareholders approve reverse split

## Summary
- CEO Stephen Willard resigns effective Oct 7, 2024; Chairman Jonathan Javitt appointed interim CEO.
- Stockholders approved reverse stock split authorization (1:2 to 1:5) at board's discretion within one year.
- Stockholders approved issuance of shares upon redemption of convertible note and warrants to institutional investors.
- Company signed LOI to acquire an interventional psychiatry clinic; targeting $25M+ initial HOPE Therapeutics business and $100M+ revenue by next year.

## SEC filing metadata
- accession: 0001437749-24-031133
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/nrxp20241011_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031133
- JSON: https://secwatch.observer/filing/0001437749-24-031133.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031133.txt

## Key facts
- Executive change
  Jonathan Javitt was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm
- Executive change
  Stephen Willard resigned as Chief Executive Officer at NRX Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774924031133/0001437749-24-031133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.